Researchers at INST Mohali have pioneered a new multifunctional therapy for Alzheimer's. Their approach uses specially designed nanoparticles that combine compounds from green tea, a neurotransmitter, and an amino acid. This innovative treatment simultaneously tackles four major pathological features of the disease. Early results from models show it can break down toxic plaques and even improve memory function.
December 17, 2025
Alzheimer's Breakthrough: How Green Tea Nanoparticles Target Brain Plaques and Memory Loss
Novel therapy integrates green
tea antioxidant, dopamine, and tryptophan into a single nanoparticle
Targets amyloid plaques,
oxidative stress, inflammation, and neuron loss simultaneously
Functionalized with BDNF protein
to clear toxic clumps and promote neural regeneration
Shows promise in lab and mouse
models by improving memory and disassembling harmful fibrils
INST researchers develop new
nanoparticle-based multifunctional therapy for Alzheimer's
INST Mohali researchers create a
novel nanoparticle therapy using green tea antioxidants to combat Alzheimer's
by targeting plaques, inflammation, and boosting neuron growth.
"This is a rare approach in
Alzheimer’s therapeutics which uniquely combines antioxidant, anti-amyloid, and
neurotrophic actions for the therapy. - Dr. Jiban Jyoti Panda's research
team"
Researchers at the Institute of
Nano Science and Technology (INST), Mohali, have identified a new pathway
involving nanoparticles to treat Alzheimer’s Disease (AD), said the Ministry of
Science & Technology on Tuesday.
Conventional Alzheimer’s
therapies often target only a single pathological feature, such as amyloid
aggregation or oxidative stress, yielding limited clinical benefit.
However, the new therapy involves
nanoparticles that integrate polyphenol with antioxidant properties found in
green tea, a neurotransmitter, and an amino acid.
It has the potential to treat
Alzheimer’s Disease by changing the path of the progression of the disease,
slowing it, improving memory, and supporting thinking skills, said the
researchers in the paper, published in the journal Small.
The therapy works by integrating
epigallocatechin-3-gallate (EGCG) -- an antioxidant found in green tea --,
dopamine -- a neurotransmitter important for mood -- and tryptophan -- an amino
acid involved in many cellular functions -- into a nanoparticle called
EGCG-dopamine-tryptophan nanoparticles (EDTNPs).
This enables it to simultaneously
target amyloid aggregation, oxidative stress, inflammation, and neuronal
degeneration -- four key pathological hallmarks of Alzheimer’s.
“Incorporation of Brain-Derived
Neurotrophic Factor (BDNF) -- a protein crucial for the survival, growth, and
function of neurons onto EDTNPs (B-EDTNPs) creates a dual-action nanoplatform
that not only clears neurotoxic Amyloid Beta aggregates (protein clumps that disrupt
neural function and drive Alzheimer’s disease pathology) but also enhances
neuronal regeneration,” said the team led by Dr. Jiban Jyoti Panda from INST,
an autonomous institute of the Department of Science and Technology (DST).
“This is a rare approach in
Alzheimer’s therapeutics which uniquely combines antioxidant, anti-amyloid, and
neurotrophic actions for the therapy,” they added.
The research, conducted with
support from Dr. Ashok Kumar Datusalia (NIPER Raebareli) and Dr Nisha Singh
(Gujarat Biotechnology University), involves the synthesis of EDTNPs using
biocompatible assembly techniques like pressure-assisted hydrothermal and
electrostatic-based co-incubation methods to combine antioxidant,
neurotransmitter, and amino acid components.
These nanoparticles were then
functionalised with BDNF, producing B-EDTNPs with enhanced neuroprotective
potential.
In lab experiments and mouse
models, these nanoparticles disassembled toxic plaques, reduced inflammation,
restored balance inside brain cells, and even improved memory and learning.
Computer simulations further confirmed that the nanoparticles latch onto
harmful Amyloid beta fibrils and pull them apart at the molecular level.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment